1887
  1. Home
  2. Eurosurveillance
  3. Volume 29, Issue 2, 11/Jan/2024
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

Timely and precise influenza vaccine effectiveness (VE) estimates are needed to guide public health messaging and impact vaccine uptake immediately. Using routinely collected laboratory, vaccination and health administrative data from Alberta, Canada, we estimated influenza VE against infection for the 2023/24 season on a near real-time basis, to late December, at 61% (95% CI: 58–64) against influenza A(H1N1), 49% (95% CI: 28–63) against influenza A(H3N2) and 75% (95% CI: 58–85) against influenza B.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.2.2300709
2024-01-11
2024-12-22
/content/10.2807/1560-7917.ES.2024.29.2.2300709
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/2/eurosurv-29-2-3.html?itemId=/content/10.2807/1560-7917.ES.2024.29.2.2300709&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2023 southern hemisphere influenza season. Geneva: WHO; 2022. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-southern-hemisphere-influenza-season
  2. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2022-2023 northern hemisphere influenza season. Geneva: WHO; 2022. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2022-2023-northern-hemisphere-influenza-season
  3. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532-46.  https://doi.org/10.1056/NEJMoa2119451  PMID: 35249272 
  4. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397(10285):1646-57.  https://doi.org/10.1016/S0140-6736(21)00677-2  PMID: 33901420 
  5. Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, et al. Estimated effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. JAMA Netw Open. 2022;5(9):e2232760.  https://doi.org/10.1001/jamanetworkopen.2022.32760  PMID: 36136332 
  6. Scott AN, Buchan SA, Kwong JC, Drews SJ, Simmonds KA, Svenson LW. Using population-wide administrative and laboratory data to estimate type- and subtype-specific influenza vaccine effectiveness: a surveillance protocol. BMJ Open. 2019;9(9):e029708.  https://doi.org/10.1136/bmjopen-2019-029708  PMID: 31575570 
  7. Alberta Health. Alberta virus respiratory dashboard Edmonton: Government of Alberta. [Accessed: 9 Jan 2024]. Available from: https://www.alberta.ca/stats/dashboard/respiratory-virus-dashboard.htm
  8. Kwong JC, Buchan SA, Chung H, Campitelli MA, Schwartz KL, Crowcroft NS, et al. Can routinely collected laboratory and health administrative data be used to assess influenza vaccine effectiveness? Assessing the validity of the Flu and Other Respiratory Viruses Research (FOREVER) Cohort. Vaccine. 2019;37(31):4392-400.  https://doi.org/10.1016/j.vaccine.2019.06.011  PMID: 31221563 
  9. BC Centre for Disease Control (BCCDC). Sentinel Practitioner Surveillance Network (SPSN). Vancouver: BCCDC. [Accessed: 15 Dec 2023]. Available from: http://www.bccdc.ca/health-info/diseases-conditions/influenza/sentinel-network-spsn
  10. Kim S, Chuang ES, Sabaiduc S, Olsha R, Kaweski SE, Zelyas N, et al. Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada. Euro Surveill. 2022;27(38):2200720.  https://doi.org/10.2807/1560-7917.ES.2022.27.38.2200720  PMID: 36148674 
  11. Skowronski DM, Chuang ES, Sabaiduc S, Kaweski SE, Kim S, Dickinson JA, et al. Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23. Euro Surveill. 2023;28(5):2300043.  https://doi.org/10.2807/1560-7917.ES.2023.28.5.2300043  PMID: 36729117 
  12. Skowronski DM, Zou M, Sabaiduc S, Murti M, Olsha R, Dickinson JA, et al. Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020. Euro Surveill. 2020;25(7):2000103.  https://doi.org/10.2807/1560-7917.ES.2020.25.7.2000103  PMID: 32098644 
Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Christa+Smolarchuk&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Smolarchuk Christa</a>, <a href="/search?value1=Carla+Ickert&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ickert Carla</a>, <a href="/search?value1=Nathan+Zelyas&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Zelyas Nathan</a>, <a href="/search?value1=Jeffrey+C+Kwong&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kwong Jeffrey C</a>, <a href="/search?value1=Sarah+A+Buchan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Buchan Sarah A</a></span>. Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season. <a href="/content/ecdc">Euro Surveill.</a> 2024;29(2):pii=2300709. <a href="https://doi.org/10.2807/1560-7917.ES.2024.29.2.2300709" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2024.29.2.2300709</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 16 Dec 2023;&nbsp;&nbsp; <span class="generated">Accepted</span>: 10 Jan 2024 </span> </p>
/content/10.2807/1560-7917.ES.2024.29.2.2300709
/content/10.2807/1560-7917.ES.2024.29.2.2300709
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error